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Age-Dependent Effects of A53T Alpha-Synuclein on
Behavior and Dopaminergic Function
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Abstract
Expression of A53T mutant human alpha-synuclein under the mouse prion promoter is among the most successful
transgenic models of Parkinson’s disease. Accumulation of A53T alpha-synuclein causes adult mice to develop severe motor
impairment resulting in early death at 8–12 months of age. In younger, pre-symptomatic animals, altered motor activity and
anxiety-like behaviors have also been reported. These behavioral changes, which precede severe neuropathology, may stem
from non-pathological functions of alpha-synuclein, including modulation of monoamine neurotransmission. Our analysis
over the adult life-span of motor activity, anxiety-like, and depressive-like behaviors identifies perturbations both before and
after the onset of disease. Young A53T mice had increased distribution of the dopamine transporter (DAT) to the membrane
that was associated with increased striatal re-uptake function. DAT function decreased with aging, and was associated with
neurochemical alterations that included increased expression of beta-synuclein and gamma synuclein. Prior to
normalization of dopamine uptake, transient activation of Tau kinases and hyperphosphorylation of Tau in the striatum
were also observed. Aged A53T mice had reduced neuron counts in the substantia nigra pars compacta, yet striatal medium
spiny neuron dendritic spine density was largely maintained. These findings highlight the involvement of the synuclein
family of proteins and phosphorylation of Tau in the response to dopaminergic dysfunction of the nigrostriatal pathway.
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of age [6–8]. As pre-clinical a-Syn models of PD that may be used
to test new therapies, it is critical to determine whether the
neuropsychiatric phenotypes of a-Syn transgenic mice accurately
reflect the human disorder. Both the dopamine transporter (DAT)
and the norepinephrine transporter (NET), which are subject to
modulation by the Syn proteins in cellular trafficking models [13],
are linked to these neuropsychiatric symptoms, and are important
drug targets in the treatment of depression, anxiety, and related
mood disorders [14]. Recent work in mouse models of synucleinopathy has begun to examine non-motor aspects, including
behaviors related to the neuropsychiatric symptoms of PD, but a
comprehensive analysis remains incomplete (see detailed reviews
in [15,16]).
In pre-symptomatic A53T mice, altered locomotor activity and
loss of anxiety-like behaviors have been reported, though the effect
of A53T a-Syn varies significantly between the transgenic lines
examined [17–19]. Furthermore, the presence of depressive-like
behavior in these animals, to our knowledge, has not been
analyzed, despite the fact that depression is a frequent comorbidity of PD [20]. Behavioral changes that precede severe
A53T-related neuropathology may stem from disruption of the
normal functions of a-Syn and the other Syn family members, bSyn and c-Syn, including modulation of monoamine neurotransmission [13]. For example, we have observed recently that all
three forms of the Syn proteins can modulate DAT and are co-

Introduction
Although not diagnosed clinically until the onset of motor
impairment, Parkinson’s disease (PD) is frequently associated with
non-motor symptoms, including autonomic dysfunction, sleep
abnormalities, and neuropsychiatric disorders [1]. Neuropsychiatric co-morbidities can significantly affect quality of life, and do not
always respond to therapies targeting PD motor symptoms [2].
Nonetheless, the development of models used to study PD in preclinical research settings has been focused primarily on generating
a robust motor phenotype that recapitulates features of the human
disorder, especially a-synuclein (a-Syn) accumulation [3]. Accumulation of a-Syn in intraneuronal structures called Lewy bodies
is a neuropathological hallmark of PD, and one approach to
modeling the disease has been to create transgenic mice that overexpress the A53T mutant of a-Syn, which causes an autosomal
dominant form of PD in humans [4]. Mouse genomes have been
modified to over-express wild-type a-Syn of human origin [5], as
well as the PD-linked a-Syn mutants A53T [6–9], A30P [10],
E46K [11], and even combinations thereof [12]. The A53T a-Syn
mouse model successfully recapitulates many important features of
synucleinopathy, including age-dependent neurodegeneration [3].
Accumulation and aggregation of A53T a-Syn in the highestexpressing transgenic lines is associated with the development of
severe motor impairment resulting in early death at 8–12 months
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distributed with DAT in the mouse brain (unpublished data), and
earlier work showed that NET is modulated by the Syn family of
proteins as well [21]. In particular, our prior work suggests that
defective modulation of DAT by A53T a-Syn may contribute to
behavioral and neurochemical changes in the A53T mouse model
of PD [22,23].
The present analysis in homozygous A53T a-Syn mice over
much of the adult life-span of locomotor activity, anxiety-like, and
depressive-like behaviors identifies perturbations both before and
after the onset of motor impairment. In addition to behavioral
alterations, we show that over-expression of A53T a-Syn had agedependent effects on re-uptake of DA, and that functional
modulation of DAT in these animals was correlated with agedependent changes in the striatal accumulation of a-Syn, b-Syn,
and c-Syn. Furthermore, we report age-dependent accumulation
of phosphorylated Tau and activation of Tau kinases, which we
and others have shown co-occur in several PD models [24-29]. We
also found that, despite a significant loss of substantia nigra pars
compacta neurons, striatal synaptic density was maintained.
Together, our findings suggest a mechanism by which defective
modulation of monoamine neurotransmission by mutant A53T aSyn could be involved in the clinical manifestations of synucleinopathy.

Table 2. Tau and Tau kinase antibodies.

Targeta

Materials and Methods
Ethics Statement
All studies with animals were approved by the Georgetown
University Institutional Animal Care and Use Committee
(Protocol 10-076).

Materials

Product
Number

Source

Hostb Dilutionsc

Tau-5

Millipore

MAB361

Ms

1:1000

p-T181-Tau

Anaspec

54960-025

Rbt

1:500

p-S199-Tau

Invitrogen

44734G

Rbt

1:500

CP-13 Tau

P. Daviesd

-

Ms

1:500

p-T212-Tau

Invitrogen

44740G

Rbt

1:500

p-S214-Tau

Invitrogen

44742G

Rbt

1:500

p-T217-Tau

Invitrogen

44744

Rbt

1:500

p-T231-Tau

Invitrogen

44746G

Rbt

1:500

p-S262-Tau

Invitrogen

44-750G

Rbt

1:1000

PHF-1 Tau

P. Daviesd

-

Ms

1:500

p-S422-Tau

Abcam

ab4862

Rbt

1:500

Akt

Cell Signaling

2966

Ms

1:500

p-S473-Akt

Cell Signaling

4058

Rbt

1:500

Cdk5

Santa Cruz

sc-6247

Ms

1:500

ERK

BD Transduction

610124

Ms

1:500

p-Y204-ERK

Santa Cruz

sc-7383

Ms

1:1000
1:1000

GSK-3b

BD Transduction

610202

Ms

p-Y216-GSK-3b

BD Transduction

612313

Ms

1:1000

JNK

Cell Signaling

9252

Rbt

1:500

p-T183/Y185-JNK

Cell Signaling

9255

Ms

1:500

p38

Santa Cruz

sc-7972

Ms

1:500

p-p38

Santa Cruz

sc-166182

Ms

1:500

a

Protein or phosphorylated epitope recognized by antibody. bAntisera raised in
mouse (Ms) or rabbit (Rbt). cAntibody dilutions applied for immunoblots.
d
Antibody provided as a generous gift by Peter Davies.
doi:10.1371/journal.pone.0060378.t002

Primary antibodies used on immunoblots in this study are listed
in Tables 1 and 2. Radio-labeled dopamine ([3H]-DA, NET131,
24 Ci/mmol) and norepinephrine ([3H]-NE, NET377, 13.8 Ci/
mmol) were purchased from Perkin Elmer (Waltham, MA). All
other reagents, except where indicated, were purchased from
Sigma-Aldrich (St. Louis, MO).

Animals
Previously described mice homozygous for a mutant human
A53T-a-Syn transgene driven by the prion promoter (A53T) were
acquired from the National Institute of Aging (NIA) Mutant
Mouse Aging Colony [8]. Age-matched wild-type controls (WT)
were acquired from the NIA Aged Rodent Colony. Animals were
imported to Georgetown University at 2-12 months of age from
NIA colonies directly prior to studies and allowed to acclimate for
several days before beginning behavioral testing.

Table 1. Synuclein, transporter, and other antibodies.
Targeta

Source

Product

Hostb

Dilutionsc

a-Syn

BD Transduction

610787

Ms

1:2000

a-Syn (h)

Invitrogen

18-0215

Ms

1:500

b-Syn

Novus Biologicals

NB100-79903

Rbt

1:1000

c-Syn

Abcam

ab55424

Rbt

1:2000

DAT

Millipore

MAB369

Rt

1:2000

NET (m)

MAb Technologies

NET05-2

Ms

1:1000

b-Actin

Santa Cruz

sc-1616

Gt

1:1000

Cadherin

Abcam

ab6528

Ms

1:2000

GAPDH

Cell Signaling

2118

Rbt

1:3000

TH

Millipore

ab152

Rbt

1:300

Animal behavior
All animals were subjected to an identical battery of behavior
tests over a three week period, with at least 48 hours between each
test. Testing was conducted in a quiet (50–55 dB ambient noise),
dedicated room. Tests are described below in the order in which
they were conducted according to previously described methods
[19,21,30-32].
Open field test. Locomotor activity and anxiety-like behavior were assessed using the open field test (OFT) as described
previously [19]. The animals were placed in the center of the
activity chamber (40640 cm with clear 35 cm high walls)
equipped with a camera above to record activity. Testing lasted
for 10 min per animal. The exploratory behavior for each animal
was analyzed automatically using the ANY-maze video tracking
system (Stoelting, Wood Dale, IL). The analysis included
distinguishing activity within a center zone of the open field to
assess thigmotaxis. The chamber was divided into 16 equal

a
Protein recognized by antibody. Species specific antibodies indicated in
parentheses (h, human; m, mouse). bAntisera raised in mouse (Ms), goat (Gt),
rabbit (Rbt), or rat (Rt). cAntibody dilutions applied for immunoblots or
immunohistochemistry.
doi:10.1371/journal.pone.0060378.t001
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biochemical analyses, brain tissue was removed and processed for
synaptosomal uptake assays or protein extraction. To isolate the
striatum and hippocampus, a razor blade was first used to slice
coronally through the brain at approximately Bregma 20.5. A
wedge-shaped section of non-striatal tissue was then removed from
the rostral portion of the brain, which was then halved sagittally.
Each half striatum was then dissected away from surrounding
cortical tissues. The caudal portion of the brain was then halved
sagittally and diagonal slices were cut at 260u from the horizontal
plane, starting at the left and right ventricles and extending
through the cortex. The cortical tissue was peeled back to reveal
the surface of each half of the hippocampus, which was then
removed. Striatal and hippocampal tissues from each animal were
individually flash frozen in liquid nitrogen or processed immediately for synaptosomal uptake assays.

squares, with the center zone defined as the middle four squares
(equal to 25% of the total area of the box). Line breaks were
determined by the passage of the animal’s center from one square
into a neighboring square.
Rotarod. The rotarod apparatus (IITC Life Sciences, Wood
Hills, CA) was used to measure balance and motor coordination
[19]. During the training period, mice were allowed to explore the
cylinder of the rotarod (71 cm long with diameter 3.2 cm) for
2 min without rotation. Each mouse was then oriented with its
head opposite the direction of rotation and the drum was slowly
accelerated to a speed of 4–40 rpm over a period of 300 sec. The
latency to fall off the rotarod within this time period was recorded
(up to 300 sec). Mice received nine trials (three per day for three
consecutive days), and the mean latency to fall off the rotarod was
calculated.
Forced swim test. A previously described forced swim test
(FST) protocol [21] was adapted for mice using a glass cylinder
(15 cm diameter) filled to a depth of 13 cm with room temperature
water. Mice were pre-tested for five min 24 hours prior to the test
period. During the five min test period, animals were placed again
into the testing cylinder, and their behavior was recorded with a
horizontally-mounted camera. Videos of each animal were
assessed by a blinded observer, and scored for the behavior
present (swimming or immobility) in each five s bin. Data are
presented as number of bins spent immobile.
Elevated plus maze. The elevated plus-maze (EPM) test was
performed as described previously [19]. The elevated plus-maze
apparatus (Stoelting) was elevated 40 cm above the floor and
consisted of four arms measuring 35 cm in length and 5 cm in
width. Two of the arms (closed) were enclosed with opaque 15-cm
high walls, and two arms had no walls (open). Mice were placed
with their head in middle of the center zone at the junction of the
open and closed arms. During the 5-min test session the
exploratory behavior of each animal was analyzed using the
ANY-maze video tracking system (Stoelting). Analyses included
the time spent and number of entries into the center zone, open
arms, and closed arms. Zone entries were scored automatically by
ANY-maze when the center of the animal passed into the
respected zones. The maze was sponged clean between trials.
Animals that fell from the maze were immediately replaced in the
starting position; tracking errors were identified by review of the
recorded videos and corrected manually.
Wire hang test. The wire hang test (WHT) was used to assess
grip strength and endurance as described previously [30–32]. Mice
were placed on a wire cage top in an identical orientation and
induced to grip the wires by gently waving the cage top. The cage
top was then inverted and suspended at a height of 40 cm over an
open cage filled with bedding and excess nesting materials to
prevent injury from falling. Mice received one training session, and
were then placed on the wire hang apparatus twice per day for
three consecutive days for a total of six trials. Movement was
recorded by a horizontally mounted camera, and trials were ended
automatically by ANY-maze (Stoelting) when the animal fell from
the suspended cage top, with a maximum duration of 300 s. Some
12 month-old A53T mice were unable to hang from the wire cage;
these animals were given a score of zero s for all trials and
euthanized for tissue collection as below.

Synaptosome preparation
Synaptosomes were prepared from each animal essentially as
described with slight modifications [21,33]. Dissected striatal and
hippocampal tissues were placed in 2 mL ice cold synaptosome
isolation buffer (0.32 M sucrose, 4 mM HEPES, 1 mm EDTA;
pH 7.4) with Complete Mini Protease Inhibitor Cocktail (Roche,
Indianapolis, IN). Tissue was homogenized in glass–Teflon
homogenizers on ice, transferred to polypropylene centrifuge
tubes (Beckman, Brea, CA), and diluted to 6 mL with isolation
buffer. Brain homogenates were centrifuged at 10006g for 10 min
at 4uC. The supernatant was collected and centrifuged at
12,5006g for 15 min at 4uC, producing the synaptosome pellet.
The synaptosome pellet was resuspended in 1 mL of a modified
Kreb’s HEPES buffer (120 mM NaCl, 7.5 mM HEPES, 5.4 mM
KCl, 5 mM Tris HCl, 5 mM glucose, 1.2 mM CaCl2, 1.2 mM
MgSO4, 1.0 mM ascorbic acid, 1.0 mM pargyline HCl; pH 7.4).
The protein concentration was determined by Lowry assay
(Biorad), the synaptosomes were diluted to 80–100 mg/mL (striatal
synaptosomes) or 250–300 mg/mL (hippocampal synaptosomes) in
modified Kreb’s HEPES buffer, and used for uptake experiments.

Synaptosomal uptake assay
Uptake assays were performed on freshly prepared synaptosomes as described previously [21,33]. Tissues from each animal
were assayed independently (no tissues were pooled), and each
data point was taken as the average of samples assayed in
triplicate. For each sample, 300 mL of the synaptosomal preparation was placed in a glass assay tube and incubated at 37uC for
10 min with shaking, followed by the addition of [3H]-DA at a
final concentration 30 nM or [3H]-NE at a final concentration of
150 nM. Uptake proceeded for 10 min and was terminated by
plunging samples into an ice water bath. Filtration was immediately performed on a 24-sample Brandel Cell Harvester (Gaithersburg, MD) and samples were collected on GF/C Whatman
filters that were presoaked in 0.1% polyethyleneimine. Filtered
samples were washed three times with 5 mL of ice cold assay
buffer. Filters were collected, scintillation cocktail was added, and
counts per minute determined using a Beckman Liquid Scintillation counter. Nonspecific uptake of [3H]-DA and [3H]-NE was
determined with the addition of 100 mM indatraline HCl or 1 mM
desipramine HCl, respectively, 5 min prior to initiation of uptake.
Additional non-specific control assays were performed in parallel
for [3H]-NE uptake with the addition of 300 nM nisoxetine HCl
or incubation at 4uC.

Tissue collection
Following completion of behavioral testing, animals were
euthanized by saline perfusion under anesthesia (intraperitoneal
10 mL/kg equithesin) or cervical dislocation. Saline perfused
animals were further perfused with 4% paraformaldehyde in
preparation for immunohistochemical analysis (see below). For
PLOS ONE | www.plosone.org
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Frozen intact brain tissues stored at 280u C were thawed briefly
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HCl, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 250 mM
sucrose, pH 7.4) with Complete Mini Protease Inhibitor Cocktail
(Roche) and Halt Phosphatase Inhibitor Cocktail (Thermo
Scientific, Rockford, IL). Homogenate protein concentration was
determined by Lowry assay (Biorad), adjusted, and aliquots were
frozen at 280uC until further extraction by various methods.
Cholate extraction. Previously described methods were used
to prepare total lysates [27]. Briefly, to solubilize protein, sodium
cholate (20% in water, wt/vol) was added to a final concentration
of 1% (vol/vol) and samples were incubated for one hour with
rotation before being processed for immunoblots.

fractionator sampling design [38–40]. Counts were made at
regular predetermined intervals (x = 140 mm, y = 140 mm). Systematic samples of the area occupied by the nuclei were made
from a random starting point. An unbiased counting frame of
known area (45 mm635 mm) was superimposed on the image of
the tissue sections using stereology software (MBF, Stereo
Investigator) utilizing a 636objective lens (Leica, N.A.1.36).
Experimenters were blinded to the treatments of each of the
groups.

Preparation of Triton X-100 soluble and insoluble
fractions. The aggregation state of a-Syn was analyzed based

Brains were removed and right hemisphere was placed in
solutions provided in the Rapid GolgiStain Kit (FD NeuroTechnologies, Ellicott City, MD) to perform Golgi impregnation
according to the manufacturer’s instructions. Primary dendrites
from medium spiny neurons (MSN) of the striatum were analyzed
blindly. Six cells per animal that were well impregnated, clearly
distinguishable from adjacent cells, and with continuous, unbroken
dendrites were chosen for analysis as described previously [41].
Spines were counted with an oil objective (1006) using a Nikon
Eclipse E400 microscope and the entire dendritic length visible
was measured using Spot Advanced Microscopy software (SPOT
Imaging Solutions, Diagnostic Instruments, Inc., Sterling Heights,
MI). Spine density was calculated by dividing the number of spines
by the length of the dendrite and data was expressed as number of
spines per 10 mm of dendrite.

Analysis of striatal synaptic spine density

on its differential solubility in 1% Triton X-100, as described
previously [24,34]. Briefly, tissue homogenates were extracted in
solubilization buffer (20 mM Tris-HCl, 50 mM NaCl, 1% Triton
X-100, pH 7.4) with Complete Mini Protease Inhibitor Cocktail
(Roche) and Halt Phosphatase Inhibitor Cocktail (Thermo
Scientific). Lysates were incubated for 30 min on ice, followed
by centrifugation at 15,0006g for 60 min at 4uC and supernatant
was collected as the Triton X-100- soluble fraction. The Triton X100-insoluble pellets were re-dissolved in the same volume of lysis
buffer containing 2% SDS [34] then analyzed by immunoblot.
Synaptosomal plasma membrane extraction. A plasma
membrane fraction was isolated from synaptosomes as described
previously [35,36]. Briefly, synaptosomes were prepared as
described above then lysed by hypo-osmotic shock and homogenization in ice cold water with protease inhibitors. HEPES was
immediately added to a final concentration of 4 mM and
synaptosomes were incubated 30 min then centrifuged at 30000
RCF for 20 min to yield the synaptosomal membrane pellet.
Pellets were extracted with the addition of nonidet P-40 (1%),
sodium deoxycholate (0.5%), and SDS (0.1%) before analysis by
immunoblot.

Statistical analysis
Results are expressed as mean 6 standard error of the mean
(SEM) unless stated otherwise. Behavior tests and immunoblots
comparing the genotypes at each age are analyzed using 2-way
ANOVA, with Bonferroni post-tests performed between A53T
and WT at each age (2, 4, 8, and 12 months). Immunoblot analysis
involving age-dependent changes are analyzed by 1-way ANOVA
within each genotype. Unless noted, all other comparisons are
made using un-paired two-tailed t-tests. Statistical significance was
accepted at P,0.05 and is denoted with a single asterisk (*).
Additional statistical distinctions are made at P,0.01 (**) and
P,0.001 (***).

Immunoblot analysis
Samples were combined 1:1 with Laemmli Sample Buffer (BioRad) containing 5% b-mercaptoethanol. Samples were boiled for
5 min, cooled to room temperature, loaded on 10–20% Tris-HCl
Criterion gels (Bio-Rad), separated by electrophoresis, and
electroblotted onto polyvinylidene fluoride membranes. After
blocking with 20 mM Tris-buffered saline, pH 7.6 containing
0.1% Tween 20 and 5% (wt/vol) blotting grade blocker non-fat
dry milk (Bio-Rad) for 1 hour at room temperature, primary
antibodies were applied overnight at 4uC in blocking buffer at
manufacturer recommended dilutions. Washed immunoblots were
incubated for 2 hours at room temperature with HRP-conjugated
secondary antibodies (1:3000; Santa Cruz) and proteins were
revealed by enhanced chemiluminescence (Perkin Elmer, Waltham, MA). Immunoblot films were digitized with an Epson
Perfection V700 Photo Scanner and quantified using ImageJ.

Results
Reduced locomotion and age-dependent loss of motor
performance in A53T mice
To assess locomotor activity and motor performance, homozygous A53T mice were compared to WT mice at 2, 4, 8, and 12
months on several behavior tests (see Materials and methods)
including the open field test (OFT), elevated plus maze (EPM),
rotarod, and wire hang test (WHT). At all ages, A53T mice
showed significantly reduced locomotor activity compared to WT,
as quantified by line breaks on the OFT (Fig. S1A) and distance
traveled on both the OFT (Fig. 1A) and the EPM (Fig. S1B).
Rotarod latency to fall was also reduced in A53T mice at 2, 4, and
12 months (but not 8) compared to WT (Fig. 1B). Latency to fall
on the rotarod declined with aging at a similar rate in both
genotypes, and suggested relatively minor impairment of coordination in A53T mice (Fig. S1C). The reduced activity level of
A53T mice was also evidenced by occupancy plots from the OFT
and on the inverted grid of the WHT (Fig. 1D). Though baseline
motor activity was reduced at all ages, the strength and endurance
measured by the WHT were not affected until advanced ages.
Latency to fall on the WHT was significantly reduced only in 8
and 12 month-old animals (Fig. 1C). Together, these data
indicated a reduced level of locomotor activity in homozygous

Immunohistochemistry and stereological counting of
substantia nigra pars compacta neurons
The 4% paraformaldehyde perfused brains were transferred to
4% paraformaldehyde solution overnight, then transferred to 30%
sucrose in PBS and stored at 4uC for approximately one week.
Brains were serially sectioned using a cryostat (Leica) at a thickness
of 30 mm, sampling 1 in 3 sections through the substantia nigra
pars compacta (SNpc). A complete series of SNpc sections was
used for TH immunohistochemistry (1:300, Millipore, USA) as
described previously [37] and counter stained for Nissl substance
with neutral red (Nissl, Grale Scientific, Victoria, Australia). The
total number of DA neurons in the SNpc was estimated using a
PLOS ONE | www.plosone.org
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through the progressive loss of motor function. On the OFT the
center zone entry count was significantly reduced at all ages in
A53T mice (Fig. S2A). This corresponded with a reduced overall
activity level (Fig. 1A), and when taken as a fraction of total entries,
OFT center zone entries were unchanged (Fig. 2A). Time spent in
the OFT center zone, however, was significantly elevated in A53T
mice at 12 months (Fig. 2B), producing a clearly observable shift to
the center in the OFT occupancy plot (Fig. 1D). On the EPM, the
fraction of outer arm entries was increased at 12 months (Fig. 2C),
while time spent in the EPM outer arms was significantly increased
at 4, 8, and 12 months (Fig. 2D). Total outer arm entry counts
were unchanged at 2 and 12 months, with significant decreases in
4 and 8 month-old A53T mice (Fig. S2B). Nonetheless, the lack of
aversion for the EPM open arms was apparent in the occupancy
plots, which show that older A53T mice spent a significant amount
of the time on the outer arm at the EPM junction (Fig. 2E). Thus,
A53T mice demonstrated a consistent loss of anxiety-like behavior
with aging, failing at later ages to manifest stereotypical behaviors
including thigmotaxis and avoidance of exposure.
A53T mice also showed reduced depressive-like behavior with
aging as indexed by the FST (see Methods). At 2 months, A53T
mice scored similarly to WT animals, spending on average about
half of the testing period in an immobile posture (Fig. 2F). In older

A53T mice that was apparent at all ages, while pronounced loss of
function was observed only in 8 and 12 month-old mice. The
development of strength and endurance impairments at 8 months
corresponds well with the previously reported timing of severe
motor impairment in several high-expressing A53T mouse lines
[6–8]. Symptomatic mice were largely or completely unable to
perform on the WHT, with latency of less than 20 s. Though the
observed motor phenotype was largely consistent with previous
reports, there was no indication that homozygous A53T mice in
this study were hyperactive at any age; indeed, A53T mice were
consistently less active than age-matched WT animals.

Age-dependent loss of anxiety-like and depressive-like
behavior in A53T mice
Behavior on the OFT and EPM was also monitored for classical
anxiety-like phenotypes, including thigmotaxis and aversion for
elevated or open spaces. We have shown previously that
hemizygous A53T mice have decreased anxiety-like behavior
with aging [19], and others have found reductions in anxiety
related phenotypes in 2 month-old homozygous mice [42], though
older animals were not studied. Here we examined the homozygous A53T mice at 2, 4, 8, and 12 months to assess the
development of anxiety-like behavior across the adult life span and

Figure 1. Motor activity and function. Open field (OFT), rotarod, and wire hang tests (WHT) were performed on WT and A53T mice at 2–12
months of age (n = 14–18 per group) to analyze motor activity and function. (A) Total distance traveled on the OFT was measured over a ten min
period by automated video tracking using ANY-maze software. (B) Latency to fall on the rotarod was recorded by a blinded observer in nine trials
performed over three days. (C) Latency to fall from the inverted grid on the WHT was recorded by automated video tracking using ANY-maze
software. (D) Heat map occupancy plots from the OFT and WHT were averaged from recorded behavior of all animals in each group. Results are
presented as mean 6 SEM and were analyzed by two-way ANOVA with Bonferroni post-hoc tests comparing each A53T group to age-matched
controls (**p,0.01; ***p,0.001).
doi:10.1371/journal.pone.0060378.g001
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Figure 2. Anxiety-like and depressive-like behavior. Anxiety-like behavior was analyzed by the OFT and elevated plus maze (EPM) on WT and
A53T mice at 2-12 months of age (n = 14–18 per group). (A) Center zone entries and (B) time on the OFT, and (C) open arm entries and (D) time on the
EPM were measured by automated video tracking using ANY-maze software. (E) Heat map occupancy plots from the EPM were averaged from
recorded behavior of all animals in each group. Depressive-like behavior was determined from the (F) immobility score and (G) latency to first
immobility on the forced swim test (FST). Behavior was monitored from video recordings by a blinded observer counting the number of 5 s bins each
animal spent in an immobile posture. 12 month-old A53T immobility score data is split into non-symptomatic (A53T 12MO; filled red circles) and
symptomatic (A53T 12MO sympto.; open red circles). Results are presented as mean 6 SEM and were analyzed by two-way ANOVA with Bonferroni
post-hoc tests comparing each A53T group to age-matched controls (*p,0.05; **p,0.01; ***p,0.001).
doi:10.1371/journal.pone.0060378.g002
PLOS ONE | www.plosone.org
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compared to corresponding 2 month-old mice (WT, 273 +/
277%, P,0.01; A53T, 320 +/2128%; Fig. 4B). Regression
analysis of immunoblot data confirms that expression of synuclein
family members a-Syn and b-Syn increased with age in A53T
mice, while c-Syn accumulated with age in both A53T and WT
mice (Table 3). There is evidence that accumulating a-Syn in the
striatum is in part composed of synuclein oligomers. While high
molecular weight a-Syn is absent in Triton X-100 soluble fractions
(Fig. 4C), 4, 8, and 12 month-old A53T have detectible oligomeric
species (Fig. 4D). These species are absent at all ages and in both
fractions from WT mice.
Over-expression of both a-Syn and b-Syn was readily apparent
in the hippocampus (Fig. S4A) but the effect of aging was absent,
with roughly the same increase in hippocampal synuclein load
present in A53T mice at all ages, and no change in c-Syn
expression (Fig. S4B). Oligomeric a-Syn was not detected in the
hippocampus (Fig. S4C-S4D), which is consistent with previous
reports showing the absence of hippocampal a-Syn inclusions in
aged A53T mice [8]. Taken together, increased expression of bSyn and c-Syn and the shift in solubility of A53T a-Syn constitute
a change in the relative bioavailability of the various Syn proteins
in the striatum.

A53T mice, however, FST immobility scores declined, indicating
that the animals spent more of the test period swimming or
attempting to escape. Immobility was significantly reduced in 4
and 8 month-old A53T mice (Fig. 2F). At 12 months the FST
behavior of A53T mice diverged depending on the deterioration of
motor function. In symptomatic 12 month-old A53T mice (WHT
latency,20 s) the trend toward decreased depressive like behavior
was reversed, as these animals had significantly elevated immobility scores compared to age-matched WT (Fig. 2F), while
average immobility scores for non-symptomatic 12 month-old
A53T animals stayed low. Surprisingly, while the total immobility
score decreased with aging, the latency to first immobility was
significantly decreased in A53T mice at all ages (Fig. 2G). A53T
mice of all ages tended to freeze immediately upon entering the
water, though these animals on average generated reduced
immobility scores across the test period. Together, OFT, EPM,
and FST data indicate an overall reduction in anxiety-like and
depressive-like behavior in aging A53T mice.

Monoamine transporter distribution and re-uptake
capacity
To probe the possible involvement of DA and NE re-uptake in
the phenotype of A53T mice, expression, distribution, and
function of DAT and NET were examined. In the striatum,
expression of DAT does not differ significantly between genotypes,
nor is there an effect of aging (Fig. 3A–3B). Immunoblot analysis of
a synaptosomal plasma membrane fraction (SPM) showed,
however, that DAT levels were significantly elevated at the cell
surface in the striatum of 2 and 4 month-old A53T mice, but not
older ages (Fig. 3A, 3C). Similarly, striatal synaptosomes also had
an increased capacity for uptake of [3H]-DA at 2 and 4 months in
A53T mice, while uptake of [3H]-DA is comparable to WT in
older animals (Fig. 3D). Unlike striatal DAT, expression and SPM
distribution of NET in the hippocampus were unchanged at all
ages (Fig. S3A-S3C). Though uptake of [3H]-NE into hippocampal synaptosomes was decreased slightly in A53T mice at some
ages (Fig. S3D) there was no consistent effect of aging. It remains
unclear how Syn proteins affect NE dynamics in the mouse brain,
with some effects on NE levels in A53T mice [43] and re-uptake of
NE in A30P mice [44] reported previously. Membrane distribution and re-uptake function of DAT, however, were consistently
elevated in younger A53T animals, but normalized at older ages
(Fig. 3D).

Age-dependent activation of Tau kinases and
accumulation p-Tau
Increased uptake of DA (see Fig. 3) implies an excess of
intracellular DA in the striatum, which is a known promoter of
oxidative stress and has been linked to neurodegenerative
processes [45,46]. Dopaminergic toxins that produce significant
oxidative stress can simultaneously induce hyper-phosphorylation
of Tau (p-Tau), a marker of neurodegenerative pathology, through
an a-Syn dependent mechanism [47–49]. Indeed, we and others
have shown that p-Tau, hyper-phosphorylated at numerous sites,
accumulates in the striatum and other brain regions in mouse
models of PD, including a-Syn transgenic mice [24,25,28] as well
as mice treated with PD-linked agricultural toxin paraquat [27].
As a measure of neuropathological progression in A53T mice,
accumulation of PHF-1 Tau (phosphorylated at Ser396/Ser404),
an indicator of Tau hyper-phosphorylation, was initially analyzed
by immunoblot in the striatum (Fig. 5A) and hippocampus
(Fig. S5A) of 2, 4, 8, and 12 month-old animals. In accordance
with previous work, PHF-1 Tau was significantly elevated in the
striatum of 4 (201659%, P,0.05) and 8 month-old A53T animals
(161657%, P,0.05, Fig. 5B). An activating phosphorylation at
Y216 of GSK-3b (p-GSK-3b), a Tau kinase, was also increased in
these animals, although at a later age (38617%, P,0.05, Fig. 5B).
Accumulation of p-Tau and increased phosphorylation of GSK-3b
were not observed in the hippocampus (Fig. S5A-S5B). Thus, in
the striatum where DAT trafficking is disrupted and Syn protein
accumulation occurs, p-Tau formation and activation of GSK-3b
also increase. Where age-dependent Syn protein accumulation
and dopaminergic dysfunction are absent, PHF-1 Tau and pGSK-3b increases are likewise not observed. This is consistent
with our prior observation that hyper-phosphorylation of Tau in
PD brains is largely restricted to striatal tissues [50], where
dopaminergic innervation is the highest [51].
Early PHF-1 Tau accumulation in the striatum occurred prior
to significant activation of Tau kinase GSK-3b. In order to identify
other kinases potentially responsible for increased levels of Tau
phosphorylation, a panel of known Tau kinases was screened by
immunoblot (Fig. 5C) for expression and phosphorylation levels
(Fig. 5D). Among the additional putative Tau kinases probed, only
JNK (stress activated/Jun-amino-terminal kinase) had a consistent
pattern of increased phosphorylation (Fig. 5C), as an activating

Aged-dependent accumulation of synuclein proteins in
the striatum
To determine the progression of biochemical changes associated
with the behavioral and neurochemical phenotype of homozygous
A53T mice, Syn protein expression was analyzed at 2, 4, 8, and 12
months of age. A53T a-Syn is expressed only in A53T mice
(Fig. 4A), producing a 4–8 fold increase in the total a-Syn load in
the striatum (Fig. 4B). Striatal A53T a-Syn expression appears to
increase with age (Fig. 4A), and is significantly elevated in 12
month-old A53T mice compared to 2 month-old A53T mice
(244+/283%, P,0.01; Fig. 4B). b-Syn expression is elevated by
4–12 fold in A53T mice (Fig. 4B), and appears to increase with age
in these animals (Fig. 4A). Indeed, expression of b-Syn is
significantly increased in 12 month-old A53T mice compared to
2 month-old A53T mice (305 +/2178%, P,0.05; Fig. 4B).
Interestingly, no differences in c-Syn expression between A53T
and WT mice are present, though striatal c-Syn levels appear to
increase with age in both animals (Fig. 4A). Expression of c-Syn in
12 month-old animals of both genotypes is significantly elevated
PLOS ONE | www.plosone.org
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Figure 3. DAT distribution and function. Expression and distribution of DAT was analyzed by immunoblot on protein from (A) total lysates (TL)
or synaptosomal plasma membrane fractions (SPM). Actin or cadherin expression, respectively, were analyzed as loading controls. Representative blot
images from each genotype at each age are presented with approximate molecular mass of nearest protein ladder bands indicated (Mr). Band optical
density (OD) of (B) TL and (C) SPM DAT relative to loading controls is presented as percent of two month-old WT (mean 6 SEM) and was analyzed by
two-way ANOVA with Bonferroni post-hoc tests comparing each A53T group to age-matched controls (*p,0.05). (D) Uptake of [3H]-DA into striatal
synaptosomes isolated from WT and A53T mice at 2–12 months of age was measured in triplicate from six animals per group and is presented as
percent of age-matched WT control (mean 6 SEM). Non-specific uptake was determined in the presence of 100 mM indatraline HCl and has been
subtracted. Comparisons between WT and A53T a-Syn at each age were made by t-test (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0060378.g003

phosphorylation of the p54 isoform of JNK at T183 and Y185 (pJNK) was significantly elevated in A53T mice at 4 and 8 months
(Fig. 5D). JNK has been shown previously to phosphorylate many
sites of full length Tau [52], and is activated in the A30P a-Syn
mouse model of synucleinopathy [28]. Therefore, antibodies
specific to these phosphorylation sites of Tau were used to probe
for accumulation of p-Tau (Fig. 6A). Several additional sites that
are known JNK substrates were increased at different time points,
including pS181, pS199, CP-13, pT212, and pS262 (Fig. 6B).
The integrity of the dopaminergic nigrostriatal pathway was
also analyzed. In agreement with our previous work [24], a
significant loss of total and TH-expressing neurons was detected in
the substantia nigra pars compacta (SNpc) of aged A53T mice
(Fig. 7A–7B). Surprisingly, despite the loss of SNpc neurons, total
DAT expression was not affected over the life span of A53T mice
(Fig. 3A–3B), consistent with compensatory sprouting of DA
terminals [38]. Likewise, striatal post-synaptic integrity appeared
to have been largely maintained, as dendritic spine counts on
medium spiny neurons (MSN) in this brain region are unchanged,
even in aged animals (Fig. 7C–7D). Together, these data indicate
partial sparing of striatal connectivity despite neuronal losses in the
PLOS ONE | www.plosone.org

SNpc and severe synucleinopathy known to exist in other brain
regions [6–8].

Discussion
Our documentation of motor impairment, behavioral perturbations, altered neurochemical function, and the development of
synucleinopathy and tauopathy over the adult lifespan of A53T
mice provides a novel view of these processes in a well-studied PD
model. Our analysis has clarified the relationship between the
motor phenotype of these mice and the apparent loss of anxietylike behavior, suggesting that the latter is largely a consequence of
or at least concomitant with reduced locomotion. In addition, the
results of our study illustrate two phenomena critical to our
understanding of how the Syn proteins function in both normal
and pathological circumstances.
First, we provide evidence that a change in the local
concentration of a-Syn, b-Syn, and c-Syn can be associated with
functional modulation of DAT in the mouse brain. In cellular
models of DAT trafficking, A53T a-Syn binds poorly to DAT and
fails to modulate DAT trafficking to the cell surface [22,53].
8
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Figure 4. Synuclein accumulation and aggregation in the striatum. (A) Expression of Syn proteins was analyzed by immunoblot on striatal
total lysates with actin expression analyzed as a loading control. (B) Band optical density (OD) relative to actin is presented as percent of two monthold A53T mice (A53T human a-Syn) or two month-old WT (total a-Syn and endogenous Syn proteins) and was analyzed by two-way ANOVA with
Bonferroni post-hoc tests comparing each A53T group to age-matched controls (mean 6 SEM; *p,0.05; **p,0.01). (C) Solubility of a-Syn was
analyzed by immunoblot on striatal homogenate extracted with 1% TX-100 and centrifuged at 15,000 RCF for 60 min. Insoluble pellets were further
extracted with the addition of 2% SDS and fractions were analyzed in parallel by immunoblot. Representative blot images from each genotype at
each age are presented with approximate molecular mass of nearest protein ladder bands indicated (Mr).
doi:10.1371/journal.pone.0060378.g004

trafficking incompetent A53T a-Syn results in increased localization of DAT to the cell surface. Uptake of DA through DAT was
normalized in older animals where bioavailability of A53T a-Syn
was reduced and expression of b-Syn and c-Syn was increased.
Indeed, we have observed recently that all three wild-type Syn
proteins have a similar capacity to modulate DAT distribution
(unpublished data). The normalization of DA uptake with aging
may therefore relate to a shift in modulation of DAT from a-Syn
to the other Syn proteins b-Syn and c-Syn. The progressive
removal of trafficking-incompetent A53T a-Syn and replacement
with b-Syn and c-Syn may also indicate a compensatory response
involved in the restoration of normal DAT trafficking. The effects
on NET of A53T a-Syn have not been examined previously, and
though a-Syn-NET and a-Syn-DAT interactions are mediated by
the same NAC region [22,23], these studies produced no
conclusive result regarding the modulation of NET by A53T aSyn.
Second, we propose that mis-trafficking of DAT in the presence
of excess A53T a-Syn contributes to biochemical alterations in the
striatum, including increased levels of hyper-phosphorylated Tau
(p-Tau). We have shown that over-expression of traffickingincompetent A53T a-Syn in young mice leads to increased DAT
distribution to the cell surface and elevated intracellular DA
exposure. Subsequent to these changes in DA uptake we observe
increased activation of JNK and Tau hyperphosphorylation at
several JNK-targeted epitopes. Importantly, phosphorylation at
the PHF-1 epitope and other p-Tau sites in the striatum appeared

Similarly, DA uptake and DAT distribution to striatal membranes
are increased in young A53T mice where bioavailability of
abundant A53T a-Syn is highest. This supports the view that the
loss of a-Syn modulation of DAT through over-expression of
Table 3. Regression analysis of synuclein expression.

Genotype
A53T

WT

Synuclein protein Slopea

R2

p-valueb

human A53T a-Syn

22.16

0.4148

0.0022

total a-Syn

17.80

0.2835

0.0156

b-Syn

29.97

0.3355

0.0074

c-Syn

40.20

0.4971

0.0005

human A53T a-Syn

NAc

NAc

NAc

total a-Syn

8.256

0.1786

0.0634

b-Syn

-0.6978

0.0010

0.8922

c-Syn

31.77

0.5121

0.0004

a
Slope calculated from linear regression of immunoblot optical density of the
indicated Syns measured at 2-12 months, where 2-month-old mean of
respective genotypes is set to 100% and all other values are expressed relative
to 2-month-old level (also measured as percents, see Fig. 4). Slope units are
percent change per month of age. bStatistical test for non-zero slopes for each
regression analysis. Statistically significant p-values (,0.05) are bolded. cHuman
A53T a-Syn is not present in WT mice.
doi:10.1371/journal.pone.0060378.t003
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Figure 5. Accumulation of PHF-1 Tau and Tau kinase activation. (A) Phosphorylation of Tau protein at the PHF-1 epitope, expression of Tau
kinases, and phosphorylation of kinases at activating sites was analyzed by immunoblot. (B) Band optical density (OD) relative to appropriate loading
controls is presented as percent of 2 month-old WT (mean 6 SEM) and was analyzed by two-way ANOVA with Bonferroni post-hoc tests comparing
each A53T group to age-matched controls (*p,0.05).
doi:10.1371/journal.pone.0060378.g005

to resolve after 8 months, which correlated with the restoration of
DA uptake to normal levels. Tau phosphorylation returned to
normal levels at all but one site in 12 month-old A53T mice,

PLOS ONE | www.plosone.org

indicating that p-Tau accumulation is transient and not likely to be
contributing to alterations in DAT trafficking or function. Thus,
despite significant loss of SNpc neurons and severe synucleino-
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Figure 6. Screen for additional pJNK-Tau sites in striatum. (A) Phosphorylation of Tau protein at epitopes subject to phosphorylation by JNK
was analyzed by immunoblot. (B) Band optical density (OD) from phosphorylation-specific probes relative to total Tau expression is presented as
percent of 2 month-old WT (mean 6 SEM) and was analyzed by two-way ANOVA with Bonferroni post-hoc tests comparing each A53T group to agematched controls (*p,0.05).
doi:10.1371/journal.pone.0060378.g006

activation, increased Tau phosphorylation, and changes in Syn
expression. It is currently unknown whether these events are
coordinated, and the mechanisms involved have not been
identified. A proposed compensatory response involving increased
expression of Syn family members b-Syn and c-Syn is consistent
with evidence for redundancy between the three Syn proteins that
is regulated at the transcriptional level [60], and indicates the need
for further investigation into the mechanisms that control Syn
gene expression.
Here, we have attempted to overlay changes in the integrity and
function of the nigrostriatal pathway with age-dependent changes
in anxiety-like and depressive-like behavior, as well as accumulating motor dysfunction. Perhaps the most consistent behavioral
feature of A53T mice was a reduced level of locomotor activity
which was evident on varied analyses from several different tests.
This is consistent with increased clearance of DA from striatal
synapses, although increased uptake of DA is not likely to be the
only factor involved in the reduced activity. To provide context, it
should be considered that DAT over-expressing mice have

pathy known to occur throughout the brain stem and spinal cord
[8,54], striatal structural integrity appears to have been largely
preserved. The transient nature of increased Tau phosphorylation
and lack of striatal pathology suggests that observed changes in
endogenous Syn protein expression at later ages could have
restored Syn-dependent DAT trafficking and therefore be involved
in alleviation of DA-induced stress kinase signaling.
Modulation of DAT trafficking through a direct interaction with
a-Syn was initially described over ten years ago [55], and
subsequent work has identified several potential mechanisms that
could contribute to trafficking of DAT by a-Syn [56] as well as the
other Syn family proteins b-Syn and c-Syn (unpublished data).
While modeling of Syn-DAT trafficking in mammalian cell culture
has been informative, prior studies have been unsuccessful in
detecting Syn modulation of DAT, with most reporting negative
findings [57–59]. These results therefore constitute the first
evidence for a dynamic relationship between Syn protein
concentration and DAT function in the mouse brain. Of particular
interest is the correlation between excess DA uptake, stress kinase
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Figure 7. Assessment of nigrostriatal neuropathology. (A) Representative images show anatomical extent of TH-expressing neurons in young
(two months) or aged (12 months) WT and A53T mice. (B) Abundance of TH-expressing (TH+) and total neurons in the substantia nigra pas compacta
(SNpc) was analyzed by quantitative stereology in young (2–4 months) and aged (8–12 months) mice (n = 5–10 per group). Data are presented as
mean6SEM and were analyzed by two-way ANOVA with Bonferroni post-hoc tests comparing each A53T group to age-matched controls (*p,0.05;
***p,0.001). (C) Representative images show dendritic spine morphology in striatal medium spiny neurons from 10 month-old WT and A53T mice.
(D) Dendritic spine density was quantified from six spines per animal in young (two months) and aged (10 months) mice (n = 3–6 animals per group).
Data are presented as mean 6 SEM and were analyzed by t-tests comparing each A53T group to age-matched controls; no significant differences
detected.
doi:10.1371/journal.pone.0060378.g007

could have the additional effect of exacerbating the perturbation of
DA release, and thus may simultaneously contribute to the overall
lowered activity level.
The decreased immobility scores on the FST in older A53T
mice are more difficult to align with what is known about the
reduced dopaminergic function and motor activity in these
animals. The FST primarily measures the behavioral response to
entrapment, with swimming and climbing behaviors viewed as an
attempt to escape, while immobility is viewed as an indication of
stress-induced despair or depression [15]. It is important to note
that while less active in the OFT and EPM, A53T mice were more
active in the FST, with reduced immobility scores (increased
swimming) at 4 and 8 months. The pattern of reduced depressivelike behavior diverged dramatically at 12 months, as symptomatic
A53T mice (WHT latency,20 s) adopted an immobile posture
throughout the FST period, while asymptomatic A53T animals
maintained lower immobility scores compared to WT. The
increase in FST immobility scores in symptomatic A53T mice
suggests that increased depressive-like behaviors observed in other

increased striatal DA clearance of a similar magnitude, yet no
change in basal locomotor activity [61]. This suggests that the
reduced activity level of the A53T a-Syn mice is only partially
dependent on the increase in DA uptake. Furthermore, the
enhancement of striatal DA uptake fades with aging, yet
locomotor activity remains low, and motor strength and endurance are additionally lost. A related mouse model of A53T a-Syn
over-expression with a similar reduction in locomotor activity [6]
also exhibited robust changes in both pre-synaptic and postsynaptic dopaminergic function including increased striatal DA
content, enhanced expression of DA receptors, and reduced
expression of DA metabolizing enzymes [62]. This reflects a
circumstance where DA neurotransmission is impaired, resulting
in sensitization of the synapses. These changes are consistent with
increased DA uptake capacity, but suggest that DA release
probability, a measure of the rate of DA vesicle fusion with the
synaptic membrane, may also be reduced in the presence of excess
a-Syn [63–65]. Accumulation with aging of both b-Syn and c-Syn,
though likely to normalize DAT trafficking as proposed here,
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rodent models of PD (primarily neurotoxin models) may be linked
to the acute loss of dopaminergic tissues and development of
motor impairment rather than the development of pre-motor
symptoms analogous to the co-morbidity of depression with PD
(for review see [66]). Successfully modeling the constellation of
non-motor symptoms that accompany PD, especially those that
typically occur prior to clinical diagnosis, remains a pressing goal
for pre-clinical researchers that could provide a means for testing
prophylactic treatments or other therapeutic measures [15,16].
While the A53T mouse lines are considered one of the more
successful models of PD and synucleinopathy [3], the observed
reductions in anxiety-like and depressive-like behaviors are
essentially opposite what would be predicted based on clinical
reports. In addition, some reports show that striatal DA
concentration may actually be elevated in a similar A53T mouse
model [62,65], a finding that is clearly at odds with the accepted
pathophysiology of PD [67]. Also, administration of DA or LDOPA fails to restore normal electrophysiologal properties to
striatal neurons in A53T mice [68]. Taken together with our work
here, these studies suggest that A53T mice may not be ideal for
modeling the full range of PD-associated symptoms, or at least that
only limited inferences should be drawn from A53T mouse models
with regard to the progression of sporadic PD.
In contrast, the vesicular monoamine transporter 2 deficient
mouse (VMAT2 LO) undergoes a more gradual loss of
monoamine storage capacity that is associated with increased
depressive-like behavior in aged VMAT2 LO animals [69].
Younger VMAT2 LO mice have FST immobility scores similar
to WT, suggesting that their later increase in depressive-like
behavior is linked to the progressive loss of monoamine function,
including NE and serotonin in addition to DA. This type of
functional loss is only partially reproduced in A53T mice, as a
decrease in SNpc neurons was not accompanied by a loss of
striatal MSN dendritic spine density. Previously, there was limited
reported evidence of nigrostriatal degeneration in aging A53T aSyn mice [3,43], with investigations focused primarily on severe
synucleinopathy and motor neuron losses in the spinal cord [6–
8,70,71]. More recently, we have reported that TH-expressing
neurons in the SN of A53T a-Syn mice were reduced by 30%
[24]. A similar result has been reproduced here, where a more
thorough analysis found a substantial (,20%) and statistically
significant loss of both total and TH-expressing SNpc neurons in
aged A53T a-Syn mice. These results argue against the prior
consensus that dopaminergic pathology is absent in A53T a-Syn
mice. An analysis of striatal medium spiny neurons (MSN),
however, showed that dendritic spine density was unaltered as late
as ten months in A53T a-Syn mice. While this presents difficulties
for a clear description of the dopaminergic status of these animals,
the apparent sparing of MSN spine density is not necessarily
inconsistent with a partial loss of dopaminergic innervation. MSN
make up 95% of striatal neurons, and are subdivided into several
distinct classes that are nonetheless indistinguishable in terms of
morphology or anatomical distribution [72]. Recent work has
shown that in a toxin-based mouse model of parkinsonism the
MSN sub-type expressing the D2 dopamine receptor undergoes
selective dendritic spine loss, while neighboring MSN expressing
the D1 dopamine receptor are largely unaffected [73]. Similar
works showing substantial loss of MSN dendritic spine density
typically involve lesions causing SNpc neuron loss much greater
than 20% [72], and so it is possible that the limited loss of THexpressing cells in the present study is insufficient to produce
significant dendritic spine remodeling. Furthermore, MSN subtypes were not differentiated here; future work should examine
both D1 and D2 dopamine receptor expressing cells to determine
PLOS ONE | www.plosone.org

whether these functionally distinct populations are differentially
affected in the A53T a-Syn mouse. Further analysis of striatal
function seems especially needed given the evidence presented
here and elsewhere [24] that these animals undergo SNpc cell
losses. Furthermore, we have shown that the biochemical
phenotype of A53T a-Syn mice includes excess cytosolic DA
exposure, and the time course of these changes parallel the
behavioral phenotype of these mice. We propose that the function
of increased Tau phosphorylation in this context is more complex,
being a marker of DA-induced stress kinase activation in the initial
stages that fades as DAT modulation by b-Syn and c-Syn is
restored. These findings support our view of the central
importance of a linkage between Tau hyper-phosphorylation
and the development of synucleinopathy in dopaminergic tissues,
including the progression of PD [24,25,27–29,50,74].

Supporting Information
Figure S1 Motor activity. OFT, EPM, and rotarod tests were
performed on WT and A53T mice at 2-12 months of age (n = 14–
18 per group) to analyze motor activity and function. (A) Total line
breaks (transition between any two regions) on the OFT and (B)
total distance traveled on the EPM were measured over a ten min
period by automated video tracking using ANY-maze software.
Results are presented as mean 6 SEM and were analyzed by twoway ANOVA with Bonferroni post-hoc tests comparing each
A53T group to age-matched controls (***p,0.001). (C) Linear
regression shows rate of decline in rotarod latency to fall
(WT = -9.660.9 s/month; A53T = 27.662.8 s/month). Slopes
were analyzed by t-test comparing WT to A53T (no significant
difference detected).
(TIF)
Figure S2 Anxiety-like behavior. Anxiety-like behavior was
analyzed by the OFT and EPM on WT and A53T mice at 2-12
months of age (n = 14-18 per group). (A) Total center zone entries
on the OFT and (B) total open arm entries on the EPM were
measured by automated video tracking using ANY-maze software.
Results are presented as mean 6 SEM and were analyzed by twoway ANOVA with Bonferroni post-hoc tests comparing each
A53T group to age-matched controls (*p,0.05; ***p,0.001).
(TIF)
Figure S3 NET distribution and function. Expression and
distribution of NET in the hippocampus was analyzed by
immunoblot on protein from (A) total lysates (TL) or synaptosomal
plasma membrane fractions (SPM). Actin or cadherin expression,
respectively, were analyzed as loading controls. Representative
blot images from each genotype at each age are presented. Band
optical density (OD) of (B) TL and (C) SPM NET relative to
loading controls is presented as percent of two month old WT
(mean 6 SEM) and was analyzed by two-way ANOVA with
Bonferroni post-hoc tests comparing each A53T group to agematched controls. (D) Uptake of [3H]-NE into striatal synaptosomes isolated from WT and A53T mice at 2-12 months of age
was measured in triplicate from six animals per group and is
presented as percent of age-matched WT control (mean 6 SEM).
Non-specific uptake was determined in the presence of 1 mM
desipramine HCl and has been subtracted. Comparisons between
WT and A53T a-Syn at each age were made by t-test (*p,0.05).
(TIF)
Figure S4 Synuclein accumulation and aggregation in
the hippocampus. (A) Expression of Syn proteins was analyzed
by immunoblot on hippocampal total lysates with actin expression
analyzed as a loading control. (B) Band optical density (OD)
13
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relative to actin is presented as percent of two month old A53T
mice (A53T human a-Syn) or two month old WT (total a-Syn and
endogenous Syn proteins) and was analyzed by two-way ANOVA
with Bonferroni post-hoc tests comparing two and 12 month old
A53T (no significant differences detected). (C) Solubility of a-Syn
was analyzed by immunoblot on hippocampal homogenate
extracted with 1% TX-100 and centrifuged at 15,000 RCF for
60 min. Insoluble pellets were further extracted with the addition
of 2% SDS and fractions were analyzed in parallel by
immunoblot. Representative blot images from each genotype at
each age are presented with approximate molecular mass of
nearest protein ladder bands indicated (Mr).
(TIF)

percent of two month old WT (mean 6 SEM) and was analyzed
by two-way ANOVA with Bonferroni post-hoc tests comparing
each A53T group to age-matched controls (no significant
differences detected).
(TIF)
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